Now showing items 1-1 of 1

    • Erdafitinib in BCG-treated high risk non-muscle invasive bladder cancer 

      Catto, James W.F.; Tran, Ben; Roupret, Morgan; Gschwend, Juergen E.; Loriot, Yohann; Nishiyama, Hiroyuki; Redorta, Joan P.; Daneshmand, Siamak; Hussain, Syed A.; Cutuli, Hernan J; Procopio, Giuseppe; Guadalupi, Valentina; Vasdev, Nikhil; Naini, Vahid; Crow, Lauren; Triantos, Spyros; Baig, Mahadi; Steinberg, Gary D. (2024-01-30)
      Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette–Guérin (BCG) treatment and who are ineligible for/refuse ...